21006
document
Effect of a nutritional supplement containing vitamin E , selenium , vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate : a randomised placebo-controlled study . OBJECTIVE To assess the effect of a nutritional supplement containing vitamin E , selenium , vitamin C and coenzyme Q10 on changes in serum levels of PSA in patients with hormonally untreated carcinoma of the prostate and rising serum PSA levels . METHODS Eighty patients were randomised to receive a daily supplement with either vitamin E , selenium , vitamin C , coenzyme Q10 ( intervention group ) or placebo over 21 weeks . Serum levels of PSA were assessed at baseline ( -2 , -1 , 0 weeks ) and after 6 , 13 , 19 , 20 and 21 weeks . Mean changes in log serum level of PSA , testosterone , dihydrotestosterone , luteinizing hormone and sex hormone binding globulin over 21 weeks between the verum and the placebo group were compared by analysis of covariance . RESULTS Seventy patients completed the study ( 36 verum ; 34 placebo ) . Compliance was > 90 % in all patients . In the intervention group , plasma levels of vitamin E , selenium and coenzyme Q10 increased significantly over the 21 weeks study period . No significant differences in serum levels of PSA , testosterone , dihydrotestosterone , luteinizing hormone or sex hormone binding globulin ( p > 0.2 ) were observed between the intervention and control group . CONCLUSION Our results indicate that supplementation of a combination of vitamin E , selenium , vitamin C and coenzyme-Q10 does not affect serum level of PSA or hormone levels in patients with hormonally untreated carcinoma of the prostate .
21007
Intervention_Pharmacological
nutritional supplement containing vitamin E
21008
Intervention_Pharmacological
selenium
21009
Intervention_Pharmacological
vitamin c
21010
Intervention_Pharmacological
coenzyme Q10
21011
Intervention_Pharmacological
vitamin E
21012
Intervention_Pharmacological
selenium
21013
Intervention_Pharmacological
vitamin C
21014
Intervention_Pharmacological
coenzyme Q10
21015
Intervention_Pharmacological
vitamin E
21016
Intervention_Pharmacological
selenium
21017
Intervention_Pharmacological
vitamin C
21018
Intervention_Pharmacological
coenzyme Q10
21019
Intervention_Control
placebo
21020
Intervention_Pharmacological
vitamin E
21021
Intervention_Pharmacological
selenium
21022
Intervention_Pharmacological
coenzyme Q10
21023
Intervention_Pharmacological
vitamin E
21024
Intervention_Pharmacological
selenium
21025
Intervention_Pharmacological
vitamin C
21026
Intervention_Pharmacological
coenzyme-Q10
21027
Outcome_Physical
serum levels of PSA
21028
Outcome_Physical
serum PSA levels
21029
Outcome_Physical
Serum levels of PSA
21030
Outcome_Physical
serum level of PSA , testosterone , dihydrotestosterone , luteinizing hormone and sex hormone binding globulin
21031
Outcome_Physical
plasma levels of vitamin E , selenium and coenzyme Q10
21032
Outcome_Physical
serum levels of PSA , testosterone , dihydrotestosterone , luteinizing hormone or sex hormone binding globulin
21033
Outcome_Physical
serum level of PSA or hormone levels
21034
Participant_Condition
hormonally untreated carcinoma of the prostate :
21035
Participant_Condition
with hormonally untreated carcinoma of the prostate
21036
Participant_Condition
rising serum PSA levels
21037
Participant_Sample-size
Eighty patients were randomised
21038
Participant_Sample-size
Seventy patients
21039
Participant_Sample-size
36 verum
21040
Participant_Sample-size
34 placebo )
21041
Participant_Condition
hormonally untreated carcinoma of the prostate